Q4 2024 Holdings
Filed 2025-02-14 | 107 holdings | $233.1M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc(VRTX)Call | COM | 92532F100 | $23.1M | 57,400 | 9.9% |
| Spdr SER TR(XBI)Put | S&P BIOTECH | 78464A870 | $18.0M | 200,000 | 7.7% |
| Bristol-Myers Squibb Co(BMY) | COM | 110122108 | $9.0M | 160,000 | 3.9% |
| Abbvie Inc(ABBV) | COM | 00287Y109 | $8.9M | 50,000 | 3.8% |
| Abbvie Inc(ABBV)Put | COM | 00287Y109 | $8.9M | 50,000 | 3.8% |
| Soleno Therapeutics Inc(SLNO)Put | COM | 834203309 | $7.9M | 175,400 | 3.4% |
| Arcellx Inc(ACLX)Put | COMMON STOCK | 03940C100 | $7.7M | 100,000 | 3.3% |
| Crispr Therapeutics AG(CRSP)Call | NAMEN AKT | H17182108 | $7.5M | 190,800 | 3.2% |
| Teva Pharmaceutical Inds LTD(TEVA) | SPONSORED ADS | 881624209 | $6.7M | 300,000 | 2.9% |
| TG Therapeutics Inc(TGTX)Put | COM | 88322Q108 | $6.0M | 200,000 | 2.6% |
| Blueprint Medicines Corp(2L9) | COM | 09627Y109 | $5.6M | 64,193 | 2.4% |
| Halozyme Therapeutics Inc(HALO)Call | COM | 40637H109 | $4.8M | 100,000 | 2.1% |
| Ultragenyx Pharmaceutical in(RARE)Put | COM | 90400D108 | $4.4M | 105,500 | 1.9% |
| Soleno Therapeutics Inc(SLNO)Call | COM | 834203309 | $4.3M | 94,600 | 1.8% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $4.2M | 75,000 | 1.8% |
| Astrazeneca PLC(AZN) | SPONSORED ADR | 046353108 | $3.9M | 30,000 | 1.7% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $3.9M | 56,337 | 1.7% |
| Biohaven LTD(BHVN)Call | COM | G1110E107 | $3.7M | 100,000 | 1.6% |
| Intra-Cellular Therapies Inc(ITCIEUR)Call | COM | 46116X101 | $3.6M | 43,700 | 1.6% |
| Ascendis Pharma A/S(ASND) | SPONSORED ADR | 04351P101 | $3.5M | 25,276 | 1.5% |
| Insmed Inc(INSM)Call | COM PAR $.01 | 457669307 | $3.5M | 50,000 | 1.5% |
| Agios Pharmaceuticals Inc(AGIO)Call | COM | 00847X104 | $3.4M | 102,000 | 1.4% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $3.3M | 60,000 | 1.4% |
| Soleno Therapeutics Inc(SLNO) | COM | 834203309 | $3.2M | 71,988 | 1.4% |
| Apellis Pharmaceuticals Inc(APLS)Call | COM | 03753U106 | $3.2M | 100,000 | 1.4% |
| Anaptysbio Inc(ANAB)Call | COM | 032724106 | $2.8M | 215,000 | 1.2% |
| Capricor Therapeutics Inc(CAPR)Call | COM NEW | 14070B309 | $2.8M | 200,000 | 1.2% |
| Bridgebio Pharma Inc(BBIO)Call | COM | 10806X102 | $2.7M | 100,000 | 1.2% |
| Celldex Therapeutics Inc New(CLDX)Call | COM NEW | 15117B202 | $2.5M | 100,000 | 1.1% |
| Arcus Biosciences Inc(RCUS) | COM | 03969F109 | $2.5M | 165,965 | 1.1% |
| Scholar Rock Hldg Corp(SRRK) | COM | 80706P103 | $2.3M | 53,160 | 1.0% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $2.3M | 50,620 | 1.0% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $2.2M | 131,862 | 0.9% |
| Ultragenyx Pharmaceutical in(RARE)Call | COM | 90400D108 | $2.2M | 52,300 | 0.9% |
| Relay Therapeutics Inc(RLAY) | COM | 75943R102 | $2.1M | 505,778 | 0.9% |
| Keros Therapeutics Inc(KROS)Call | COM | 492327101 | $2.1M | 130,000 | 0.9% |
| Recursion Pharmaceuticals in(RXRX)Call | CL A | 75629V104 | $2.0M | 300,000 | 0.9% |
| Scholar Rock Hldg Corp(SRRK)Call | COM | 80706P103 | $1.9M | 43,000 | 0.8% |
| Jazz Pharmaceuticals PLC(JAZZ) | SHS USD | G50871105 | $1.8M | 14,719 | 0.8% |
| Uniqure NV(QURE)Call | SHS | N90064101 | $1.8M | 100,000 | 0.8% |
| Oric Pharmaceuticals Inc(ORIC) | COM | 68622P109 | $1.7M | 214,291 | 0.7% |
| Altimmune Inc(ALT)Call | COM NEW | 02155H200 | $1.4M | 200,000 | 0.6% |
| TG Therapeutics Inc(TGTX) | COM | 88322Q108 | $1.4M | 47,805 | 0.6% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $1.4M | 114,000 | 0.6% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $1.3M | 25,900 | 0.6% |
| Anaptysbio Inc(ANAB)Put | COM | 032724106 | $1.3M | 100,000 | 0.6% |
| Vistagen Therapeutics Inc(VTGN) | COM | 92840H400 | $1.3M | 442,520 | 0.6% |
| Denali Therapeutics Inc(DNLI) | COM | 24823R105 | $1.2M | 60,000 | 0.5% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $1.2M | 14,701 | 0.5% |
| Evolus Inc(EOLS) | COM | 30052C107 | $1.1M | 97,423 | 0.5% |